{"nctId":"NCT02245022","briefTitle":"Safety and Pharmacokinetics of Dolutegravir in Pregnant HIV Mothers and Their Neonates: A Pilot Study","startDateStruct":{"date":"2017-03-14","type":"ACTUAL"},"conditions":["HIV","Pregnancy"],"count":60,"armGroups":[{"label":"Dolutegravir 50mg od","type":"EXPERIMENTAL","interventionNames":["Drug: Dolutegravir 50mg od"]},{"label":"Standard of Care","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Standard of Care"]}],"interventions":[{"name":"Dolutegravir 50mg od","otherNames":["Tivicay (ViiV Healthcare)","GSK1349572"]},{"name":"Standard of Care","otherNames":["Efavirenz 600mg od","Lamivudine 300mg od","Tenofovir 300mg od"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Able to provide informed consent\n* Willing to participate,\n* Women age 18 years and above\n* Pregnant\n* Untreated HIV infection in late pregnancy at â‰¥28 - 36 weeks gestation\n\nExclusion Criteria:\n\n* Received antiretroviral drugs in previous 6 months\n* Ever received integrase inhibitors\n* Serum haemoglobin \\< 8.0 g/dl\n* Elevations in serum levels of alanine aminotransferase (ALT) \\>5 times the upper limit of normal (ULN) or ALT \\>3xULN and bilirubin \\>2xULN (with \\>35% direct bilirubin)\n* eGFR \\< 50ml/min\n* Active Hepatitis B infection, history or clinical suspicion of unstable liver disease, or subjects with severe liver disease (Class C by Childs-Hugh criteria)\n* Severe pre-eclampsia (e.g. HELLP), or other pregnancy related events such as renal or liver abnormalities (e.g. grade 2 or above proteinuria, elevation in serum creatinine (above 2.5 x ULN), total bilirubin ALT or AST)\n* Paternal non-consent (where disclosure to male partner has been made)\n* Clinical depression or clinical judgement suggests increased risk of suicidality","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"AUC0-24 of DTG in Pregnant Women in Third Trimester and 2 Weeks Postpartum","description":"Rich PK with sampling at t0, 1, 2, 4, 6, 8 and 24 hours relative to drug dose","paramType":"GEOMETRIC_MEAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35322","spread":null},{"groupId":"OG001","value":"40127","spread":null}]}]}]},{"type":"PRIMARY","title":"Cmax of Dolutegravir","description":"Maximum plasma concentration of dolutegravir in pregnancy vs postpartum","paramType":"GEOMETRIC_MEAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2534","spread":null},{"groupId":"OG001","value":"2899","spread":null}]}]}]},{"type":"PRIMARY","title":"Trough Concentration","description":"Concentration at 24 hours after dose, immediately prior to next dose) of dolutegravir","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"642","spread":null},{"groupId":"OG001","value":"777","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Reporting Severe Adverse Events During Study Period","description":"Safety questionnaires at every scheduled and unscheduled study visit Infant safety questionnaires at all post-partum visits Self-reporting\n\nParticipants were reviewed for safety and tolerability after 7, 14 and 28 days on treatment, and after 56 days if delivery had not taken place. Following delivery, safety assessments were","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Women in Each Arm With VL < 50 Copies/mL, and <400 Copies/mL at Delivery","description":"HIV viral load will be measured at enrollment into the study and at delivery","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]}]},{"type":"SECONDARY","title":"Cord:Maternal Plasma DTG Ratio","description":"A maternal blood sample and a cord blood sample will be taken at delivery to calculate the transplacental transfer of Dolutegravir","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.21","spread":null}]}]}]},{"type":"SECONDARY","title":"Maternal Plasma: Breastmilk DTG Ratio","description":"At the timepoints indicated, a single maternal blood sample and a sample of breast milk will be taken to measure Dolutegravir levels in both matrices and allow estimation of transmammary drug exposure","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.03","spread":null}]}]}]},{"type":"SECONDARY","title":"Infant DTG Levels","description":"Infants from the Dolutegravir arm (N=30) will be randomised 1:1:1 to return for PK sampling 1, 2 or 3 days after the mother has discontinued Dolutegravir and changed to Standard of Care treatment. All infants will have a single capillary blood sample (heel prick) taken at 2 weeks postpartum, and then at the time point they have been randomised to.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number and Severity of Adverse Events and Laboratory Abnormalities","description":"Laboratory test measured routinely up until 3 days after change to standard of care. In addition, patients will remain under follow-up until 6 months postpartum, and laboratory tests will be performed if clinically indicated at any point. The routinely measured 'safety bloods' in this study are Full Blood Count, Urea and Electrolytes including eGFR, Liver Function Tests including Alanine Aminotransferase and Bilirubin","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Who Discontinue Treatment Due to Adverse Events","description":"Mothers will be switched to standard of care at 2 weeks postpartum","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Mother to Child Transmission of HIV","description":"Infant HIV testing by PCR will be undertaken at six weeks and six months of age, as per Uganda National Policy","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Pharmacogenomic Factors Influencing Transplacental and Breast Milk Transfer of Drug","description":"Frequency of relevant polymorphisms and association with drug concentrations","paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":29},"commonTop":["Low haemoglobin"]}}}